Laboratory tests for diagnosing and monitoring canine leishmaniasis by Paltrinieri, S et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Laboratory tests for diagnosing and monitoring canine leishmaniasis
Paltrinieri, S; Gradoni, L; Roura, X; Zatelli, A; Zini, Eric
Abstract: Although several reviews on canine leishmaniasis have been published, none thoroughly de-
scribed clinicopathologic abnormalities and their clinical usefulness. The aim of this review was to provide
information concerning current diagnostic tests relevant for clinical pathologists and from a practical
perspective. Specifically, in canine leishmaniasis, nonregenerative normocytic normochromic anemia,
thrombocytopenia, or leukogram changes may be present. Clinical chemistry and urinalysis may indicate
renal dysfunction (azotemia, decreased urine specific gravity, proteinuria) and an inflammatory/immune
response (increased acute phase proteins [APP] or ￿2 - and/or ￿-globulins). Although a potential gam-
mopathy is usually polyclonal, it may also appear oligo- or monoclonal, especially in dogs coinfected by
other vector-borne pathogens. When lesions are accessible to fine-needle aspiration (lymphoadenomegaly,
nodular lesions, joint swelling), cytology is strongly advised, as the presence of Leishmania amastigotes
in a pattern of pyogranulomatous inflammation or lymphoplasmacytic hyperplasia is diagnostic. If the
cytologic pattern is inconclusive, the parasite should be identified by histology/immunohistochemistry or
PCR on surgical biopsies. Alternatively, cytology and PCR may be performed on bone marrow samples
where amastigotes, along with erythroid hypoplasia, myeloid hyperplasia, plasmacytosis, or secondary
dysmyelopoiesis can be observed. Dogs with overt leishmaniasis generally have high antibody titers, while
low titers predominate in immunologically resistant infected dogs or in exposed dogs with no parasite
confirmation. Quantitative serology is recommended in clinically suspect dogs as high-titer antibodies
titers may confirm the clinical diagnosis. In confirmed and treated dogs, renal function and inflammato-
ry/immune response variables should be periodically monitored.
DOI: https://doi.org/10.1111/vcp.12413
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-128082
Accepted Version
Originally published at:
Paltrinieri, S; Gradoni, L; Roura, X; Zatelli, A; Zini, Eric (2016). Laboratory tests for diagnosing and
monitoring canine leishmaniasis. Veterinary Clinical Pathology, 45(4):552-578.
DOI: https://doi.org/10.1111/vcp.12413
1 
 
LABORATORY TESTS FOR DIAGNOSING AND MONITORING CANINE LEISHMANIASIS 1 
 2 
 3 
Running header: laboratory diagnosis of leishmaniasis 4 
 5 
Saverio Paltrinieri, DVM, PhD, Dipl ECVCP, Department of Veterinary Sciences and Public 6 
Health – University of Milan, Italy 7 
Luigi Gradoni, Unit of Vector-borne Diseases & International Health, Department of Infectious 8 
Diseases, Istituto Superiore di Sanità, Rome, Italy 9 
Xavier Roura, Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, Bellaterra, Spain; 10 
Andrea Zatelli, Medical Consultancy Services, TàXbiex, Malta 11 
Eric Zini, Clinic for Small Animal Internal Medicine, University of Zurich, Switzerland; 12 
Department of Animal Medicine, Production and Health, University of Padova, Italy; Istituto 13 
Veterinario di Novara, Granozzo con Monticello (NO), Italy. 14 
 15 
Corresponding author: 16 
Prof. Saverio Paltrinieri 17 
Dipartimento di Scienze Veterinarie e Sanità Pubblica, Università di Milano 18 
Via Celoria 10, 20133, Milano, Italy 19 
Tel 0039-02-50318103 20 
Fax 0039-02-50318095 21 
e-mail: saverio.paltrinieri@unimi.it 22 
23 
2 
 
Abstract  24 
Despite several reviews on canine leishmaniasis, none throughly described laboratory abnormalities 25 
and diagnostic tests in light of their clinical usefulness. Aim was to summarize this information 26 
from a practical perspective. Canine leishmaniasis often leads to profound clinicopathological 27 
abnormalities. CBC reveals non-regenerative normocytic normochromic anemia and 28 
thrombocytopenia, but other types of anemia or leukogram changes are also observed. Clinical 29 
chemistry and urinalysis frequently show abnormalities suggestive of renal dysfunction (increased 30 
creatinine and urea, decreased urine specific gravity, proteinuria) and inflammatory/immune 31 
activation (increased acute phase proteins or α2- and/or γ-globulins). The gammopathy is typically 32 
polyclonal but can also be oligo- or monoclonal. When lesions accessible to fine needle aspiration 33 
or other sampling techniques (lymhpoadenomegaly, nodular or ulcerated skin lesions, joint 34 
swelling) are present, cytology is strongly advised; the disease is confirmed if Leishmania 35 
amastigotes are identified and pyogranulmatous inflammation or lymphoplasmocytic hyperplasia is 36 
present. If results are inconclusive, the parasite should be identified through 37 
histology/immunohistochemistry or PCR on surgical biopsies. Alternatively, cytology and PCR 38 
may be performed on bone marrow, where amastigotes and erythroid hypoplasia, myeloid 39 
hyperplasia, plasmocytosis, or secondary dysmyelopoiesis can be observed. Dogs with overt disease 40 
generally have high antibody titers at ELISA or immunofluorescence. Low antibody titers may be 41 
found in infected dogs that are immunologically resistant, or in exposed dogs (dogs not harboring 42 
the parasite). If leishmaniasis is suspected but cytological evidence of the parasite is negative, 43 
serology is recommended for confirmation. In treated dogs, renal function and the magnitude of the 44 
inflammatory/immune reaction should be periodically monitored. 45 
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Leishmaniasis is a frequent infectious disease in dogs living in endemic areas, is associated with 51 
important morbidity and, although appropriate treatment, it can cause death. Despite several 52 
reviews have been published so far, none has fully described the diagnostic role of laboratory 53 
findings that are observed in dogs with leishmaniasis and of available tests. Therefore, the aim of 54 
the present review was to provide information concerning laboratory abnormalities and current 55 
diagnostic tests, from a practical perspective. 56 
 57 
Etiology and pathogenesis of canine leishmaniasis 58 
Canine leishmaniasis is a disease caused by the protozoan parasite Leishmania infantum 59 
(Kinetoplastida: Trypanosomatidae), or its New World synonym Leishmania chagasi.1 Although 60 
non-vectorial transmission is occasionally reported (e.g. by transplacental, transfusional or venereal 61 
route),2-4 it is assumed that canine leishmaniasis is mainly acquired by the bite of infected 62 
phlebotomine sand flies (Diptera: Psychodidae). Therefore, the geographical distribution and 63 
prevalence of the disease largely depends on the presence and abundance of competent vector 64 
species, including members of the Phlebotomus (Larroussius) subgenus in the Old World 65 
(Mediterranean Basin and Central Asia) and Luztomyia longipalpis and L. evansi in the New World 66 
(from Mexico through Argentina).5 Blood-sucking females ingest the intracellular, non-flagellated 67 
form of Leishmania (amastigote) during the blood meal on infected hosts. After multiplication, 68 
flagellated forms (promastigote) and transform into non-replicative, infectious metacyclic forms 69 
that are inoculated into the host’s dermis when the fly takes another blood meal. Parasites are 70 
phagocytosed by local and recruited host cells, and within phagolysosomes of resident macrophages 71 
promastigotes transform and replicate as amastigotes.6 72 
The pathogenesis of the disease starts with the ingestion of recently inoculated promastigotes by 73 
neutrophils that are unable to kill the protozoa but activate dermal macrophages and other 74 
mechanisms of innate immunity (e.g. acute phase response). Macrophages initially activate their 75 
antimicrobial defenses, which are based on the release of enzymes and on the production of free 76 
5 
 
radicals within the phagolysosome. Leishmania organisms are able to interfere with the oxidative 77 
activity of the phagocytes7,8 and therefore amastigotes can survive and actively replicate in 78 
macrophages, leading to cell destruction and infecting progressively more and more phagocytes. 79 
In longitudinal field studies employing naïve dogs, it has been demonstrated that Leishmania can be 80 
detected by PCR in bone marrow samples starting about 6 months from natural exposure to 81 
phlebotomine vectors.9 Once bone marrow has been colonized it is generally accepted that the dog 82 
is persistently infected. However, the same studies showed that dogs being PCR positive in bone 83 
marrow may become negative in the following months without any treatment; it is unknown 84 
whether the parasite density fluctuates below the threshold limit of the test, the infection persists in 85 
organs other than bone marrow, or the host defenses successfully eradicate the infection.9 Despite 86 
dogs can mount an antibody response after the first contact with the parasites, resistance or 87 
susceptibility to progressive infection (leading to clinical disease) depend on the balance between 88 
Th1 (cell-mediated) and Th2 (humoral) immune responses of the host: those with prevailing Th2 89 
response are more likely to have uncontrolled dissemination of parasites to all body tissues and to 90 
show lesions and clinical signs of leishmaniasis.10-13 91 
Of note, depending on the host-parasite interactions, the simple detection of circulating antibodies 92 
does not necessarily imply that the dog is actually infected and detection of parasites in tissues does 93 
not suggest that the infected dog is actually sick. Therefore, the two existing guidelines that deal 94 
with the diagnosis and staging of canine leishmaniasis, recently released by the Leishvet group14 95 
and the Canine Leishmaniasis Working Group (CLWG),15 classify dogs as exposed, infected or sick 96 
based on a combination of clinical findings and clinicopathological tests or tests for etiological 97 
diagnosis. Specifically, both guidelines include two main categories of dogs: 98 
- Infected dogs: dogs clinically unremarkable, without abnormalities in hematology, clinical 99 
chemistry and urinalysis, that test positive to PCR or cytology in tissues such as bone 100 
marrow, lymph node, spleen, skin or peripheral blood; 101 
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- Sick dogs: infected dogs that have clinical signs or clinicopathological changes consistent 102 
with leishmaniasis. 103 
The classification of the CLWG15 includes two additional categories of dogs at the extremes of the 104 
spectrum:  105 
- Exposed dogs: dogs clinically unremarkable with positive serology, in which PCR or 106 
cytology fail to demonstrate the presence of the parasite; 107 
- Severely sick dogs: sick dogs that do not respond to treatments and/or are affected by 108 
concurrent diseases. 109 
The Leishvet group classifies sick dogs in four stages according to the severity of clinical signs and 110 
magnitude of antileishmanial antibody titers.14 111 
 112 
Clinical signs of canine leishmaniasis 113 
The interpretation of clinicopathological, serological and molecular tests should be done in light of 114 
history, signalment and clinical presentation. History should focus on the risk of exposure to 115 
phlebotomine vectors. Signalment should focus on gender, breed and age; clinically overt 116 
leishmaniasis is more frequent in male dogs, Boxer and German shepherd, and in those younger 117 
than 3 years or older than 8 years, 16,17 although recent reports suggests that any dog above 2 years 118 
is at risk.18 119 
The spectrum of clinical presentations is wide and ranges from infections characterized by the 120 
absence of obvious clinical findings but detectable laboratory abnormalities, to overt clinical 121 
infections characterized by the presence of clinical and laboratory abnormalities that require or not 122 
hospitalization. However, some signs are more frequent than others. The most typical clinical 123 
findings include:14,15,19-22 generalized lymphoadenomegaly, cutaneous lesions, pale mucous 124 
membranes, weight loss or cachexia, polyuria/polydipsia, epistaxis, onicogriphosis. Ocular 125 
lesions,15,23,24 lameness, lethargy and fever are also quite common.25,26 In a longitudinal study,27 it 126 
was shown that lymph node enlargement appears first (approximately 1 year after exposure to sand 127 
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flies), followed by cutaneous lesions (after 18 months) and ocular signs (after 22 months). 128 
Furthermore, atypical forms have been described, especially in highly endemic areas, including 129 
gastrointestinal, neurological, musculoskeletal, cardiopulmonary, lower urinary tract or genital tract 130 
signs.28-36 131 
 132 
Laboratory abnormalities that may support or confirm leishmaniasis 133 
In addition to clinical findings, laboratory abnormalities detectable by routine hematology, clinical 134 
chemistry or urinalysis may further increase the clinical suspicion of canine leishmaniasis. 135 
Moreover, especially in the early phases of the disease or with atypical presentations, laboratory 136 
changes may occur in the absence of obvious abnormalities at physical examination. Therefore, a 137 
basic panel is mandatory when canine leishmaniasis is suspected or when a dog with positive result 138 
tests for etiological diagnosis needs to be classified as “exposed”, “infected” or “sick”. Table 1 139 
summarizes the clinicopathological changes that are found in dogs with leishmaniasis (i.e. “sick” 140 
dogs). 141 
 142 
1) Hematologic abnormalities 143 
Hematological changes in canine leishmaniasis are non specific.37,38 Neutrophilia, due to the 144 
systemic inflammatory response associated with the infectious diseases, may be particularly 145 
prominent if ulcerative cutaneous lesions with secondary bacterial infection are present.37,39,40 146 
Conversely, numerical or morphological changes in the other leukocyte populations are less 147 
common, although lymphopenia, lymphocytosis or eosinophilia are occasionally described39-42 148 
Amastigotes may be rarely documented in circulating leukocytes of infected dogs (0.5% of cases), 149 
within neutrophils, lymphocytes and monocytes (figure 1);41,43 the percentage of infected cells is so 150 
low that their search is generally not rewarding. When a systemic disease and blood dissemination 151 
is suspected, more sensitive tests such as PCR or quantitative PCR should be preferred to the simple 152 
microscopical examination of blood smears (see below). When parasites are found on smears, 153 
8 
 
however, it is very likely that the parasite burden is high: therefore, although, as stated above, the 154 
simple detection of the parasite does not automatically mean that the infected dog is sick, it is more 155 
likely that dogs with a high parasite burden (and parasites detected on smears) are sick than simply 156 
infected. 157 
The most common hematological changes in leishmaniotic dogs is anemia,37,38,44,45 that may appear 158 
6 months after exposure to infection.27 Anemia is usually mild to moderate and has the normocytic 159 
normochromic non regenerative pattern40,44,45 typical of the anemia of inflammatory disease, whose 160 
pathogenesis include a depression of metabolic activity of bone marrow, in this case sustained also 161 
by the infection of stromal cells by the parasite, and a decreased iron availability for 162 
erythropoiesis.46 However the pathogenesis of anemia in leishmaniotic dogs include additional 163 
mechanisms such renal failure leading to reduced erythropoietin synthesis and secondary 164 
dismyelopoiesis associated with the production of antibodies against erythroid precursors.47 165 
Moreover, it is very likely that anemia also has a hemolytic component,48 likely due to the presence 166 
of anti-RBC antibodies; in a few cases, the hemolysis may be prevalent,49 or associated with a 167 
“lupus-like” reaction along with other dermatological or systemic signs or laboratory change, 168 
including positive ANA-test50 or perinuclear antineutrophil cytoplasmic autoantibodies.51 169 
Thrombocytopenia is fairly frequent in leishmaniotic dogs without concurrent infections. It is 170 
usually mild to moderate but if severe, co-infections with other vector-borne pathogens (e.g. 171 
Ehrlichia canis, Anaplasma phagocytophilum or A. platys) or other possible causes of reduced 172 
platelet concentration should be suspected. The most likely mechanism responsible for 173 
thrombocytopenia in leishmaniasis is a peripheral consumption of circulating platelets. In turn, this 174 
mechanism may be due to immune-mediated mechanisms, since the presence of anti-Plt antibodies 175 
has been demonstrated in leishmaniotic dogs.52-54  176 
Moreover, platelet loss may be associated to hypercoagulability caused by a decreased 177 
concentration of anti-thrombin III, as in any other protein losing nephropathy55 (see below), or to 178 
disseminated intravascular coagulation (DIC) that may be occasionally suspected in leishmaniotic 179 
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dogs.56 However, the mechanism of thrombocytopenia in leishmaniotic dogs includes also a 180 
decreased production due to the depressed bone marrow activity and to the secondary 181 
dysmyelopoiesis cited above. Even in the absence of reduced platelet counts, however, platelet may 182 
be hypofunctional in dogs with leishmaniasis57 although this reduced function is rarely responsible 183 
for hemostatic abnormalities, as described below. 184 
One additional hematological test that may be run in dogs with leishmaniasis is the flow-cytometric 185 
evaluation of the CD4/CD8 ratio. The rationale for performing this test is that as soon as Th1 186 
responses decreases, thus increasing the susceptibility to the disease and favoring the shift from 187 
latent infection to overt disease, the number of CD4+ lymphocytes decreases causing reduction of 188 
the CD4/CD8 ratio.58,59 Therefore, a seropositive or PCR-positive dog with a low CD4/CD8 ratio is 189 
more predisposed to develop clinical signs than a similar dog with normal CD4/CD8 ratio. The 190 
practical applicability of this test, however, is limited by the high individual variability and by the 191 
difficulty to determine a clear cut-off for staging the disease. Hence, this test may be useful for 192 
monitoring the post-treatment follow-up, rather than to stage a dog at first diagnosis of 193 
leishmaniasis; the authors do not suggest the use of this test for diagnostic purposes in dogs 194 
suspected to have leishmaniasis. 195 
Finally, the hematological profile of leishmaniotic dogs may be completed by bone marrow 196 
cytology.27,42,44,60 This analysis may be useful in leishmaniotic dogs to confirm the infection 197 
through the detection of infected macrophages, as better specified below, but it may be also used to 198 
differentiate a simple infection from systemic disease (i.e. “infected” vs. “sick” dog).15 Despite 199 
some histological studies demonstrated that parasite density can be high despite few clinical signs,61 200 
generally the parasite load and the presence of cytological alterations increase as soon as the dogs 201 
show clinical signs.62 Therefore, rare infected macrophages may be occasionally seen in the absence 202 
of other pathological findings in dogs that are simply infected, whereas dogs in which the parasite 203 
induces an inflammatory reaction and/or a systemic disease, are characterized by a higher number 204 
of parasites detected cytologically and by a series of morphological changes. Specifically, in the 205 
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latter case cytology of the bone marrow usually reveals an erythroid hypoplasia,40 without 206 
abnormalities in the ratio between maturative and proliferative pools of erythroid precursors, 207 
occasionally associated with myeloid hyperplasia (and thus with an increased M:E ratio). Moreover, 208 
signs of bone marrow inflammation, generically defined by Stockham and Scott as “myelitis”,63, are 209 
usually found (figure 2). These include a proliferation of either infected or non-infected 210 
macrophages often with signs of erythrophagia or, more generically, cytophagia, associated with an 211 
increase of neutrophils in the framework of the myeloid hyperplasia, and a moderate to severe 212 
plasmocytosis characterized by a higher number of plasma cells with signs of activation (e.g. mott 213 
cells), and lymphocytes.64,65 Megakaryocyte hyperplasia may also be present, especially when 214 
peripheral consumption of platelets occurs. 215 
Secondary dismyelopoiesis is another common finding, although less frequent than the typical 216 
pattern listed above (figure 3). This condition is characterized by multiple peripheral cytopenias 217 
(e.g. the anemia and thrombocytopenia cited above) associated with hypercellular bone marrow on 218 
which one or more cell lineages show dysplastic features. In canine leishmaniasis, these mostly 219 
include dyserythropoiesis and dysmegakariopoiesis, while dismyelopoiesis (and in particular 220 
dysgranulopoiesis, mostly characterized by abnormal maturation and ring forms) is only 221 
occasionally found: more specifically, erythroid precursors with abnormal mitoses, asynchronous 222 
nucleo-cytoplasmic maturation, nuclear fragmentation, and/or late stage maturation arrest, 223 
especially when the pathogenesis includes an immune-mediated reaction against RBC precursors. 224 
Dwarf megakaryocytes associated or not with an increased number of megakariobkasts and with 225 
emperipolesis may be typical aspects of dysmegakariopoiesis in leishmaniotic dogs. The detection 226 
of secondary dysmyelopoiesis however, is not per se diagnostic for leishmaniasis, unless 227 
macrophages with intracytoplasmic amastigotes and other signs of reactivity (e.g. 228 
lymphoplasmocytic infiltration) are found. Therefore, the cause-effect association between 229 
secondary dysmyelopoiesis and the simple seropositivity or PCR-positivity should be carefully 230 
considered. Ultimately, in this case the diagnosis of leishmaniasis should be based on the exclusion 231 
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of other infectious, toxic or metabolic causes of secondary dysmyelopoiesis or of primary 232 
myelodysplastic syndromes (MDS) as recommended in hematology textbooks.45,47,64  233 
The last and less common finding in bone marrow cytology leishmaniotic dogs may be the presence 234 
of erythroid hyperplasia when peripheral signs are consistent with the diagnosis of immune-235 
mediated hemolytic anemia (IMHA). Also in this case, however, IMHA can be associated with 236 
leishmaniasis only if the parasite if found in cytological specimens characterized by erythroid 237 
hyperplasia. If not, the diagnostic approach should be taken into account only if any other possible 238 
cause of IMHA has been excluded. In brief, bone marrow cytology may be useful for diagnostic 239 
purposes in some dogs, by detecting amastigotes and compatible cytological abnormalities, or to 240 
differentiate between infected dogs from those that are sick due to leishmaniasis. 241 
 242 
2) Hemostatic abnormalities 243 
Hemostatic abnormalities are uncommon in leishmaniotic dogs. Activated partial thromboplastin 244 
time (aPTT) and prothrombin time (PT) may be increased; however, in most cases this is due to 245 
preanalytical factors, since their prolongation may occur when the concentration of total globulins 246 
increases, which is frequent in dogs with leihsmaniasis.66 Alternatively, prolonged coagulation 247 
times may result from DIC, although this complication is uncommon in leishmaniotic dogs.56,67 248 
Conversely, hypercoagulability may be common in leishmaniotic dogs if affected by severe protein 249 
losing nephropathy.68 This is mostly due to glomerular loss of antithrombin III (ATIII), a protease 250 
inhibitor involved in the regulation of blood coagulation that prevents the conversion of fibrinogen 251 
into fibrin. The lack of this physiologic anticoagulant may induce hypercoagulability that in turn 252 
promotes thrombosis and subsequent consumption coagulopathy. Hypercoagulability is also 253 
favored by the hyperviscosity syndrome due to increased circulating globulins.69 As in any other 254 
hypercoagulable state associated with protein losing nephropathy, hypercoagulability of 255 
leishmaniotic dogs was also demonstrated through a decreased clot formation time and an increased 256 
global clot strength using thromboelastography (TEG);70 differently, in another study the 257 
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coagulation profile of leishmaniotic dogs assessed by thromboelastometry (TEM, a technique 258 
similar to TEG) was within normal limits.71 However, it is worth noting that TEM and TEG are 259 
affected by the RBC mass, possibly explaining the different results obtained with TEM and 260 
TEG.72,73 In brief, to assess hypercoagulability in dogs with protein losing nephropathy associated 261 
with leishmaniasis the authors currently suggest including only ATIII measurement. 262 
 263 
3) Biochemical abnormalities 264 
Because the clinical presentation of dogs with leishmaniasis is variable, also the type of 265 
biochemical abnormalities varies accordingly. Renal dysfunction and inflammation/immune 266 
reactions are frequently observed and their presence should be evaluated in each dog with suspected 267 
or confirmed leishmaniasis (see below). Regarding other routine biochemical analytes that may be 268 
altered in leishmaniotic dogs, there are enzymes of hepatobiliary or pancreatic damage that may 269 
increase in case of pyogranulomatous infiltrates affecting these organs,15,16 muscular enzymes, 270 
including LDH and CK, that may increase with musculoskeletal lesion.74 Nevertheless, increased 271 
CK may also be due to the increased CK-BB isoenzyme if neurological signs are present,75 since 272 
Leishmania has been found in the brain of some affected dogs with cerebrovascular alterations,76-78 273 
or to increased CK-MB if leishmaniotic dogs have cardiomyopathy (i.e. increased tropoinin I and 274 
cardiopulmonary lesions have been reported in many leishmaniotic dogs).79-81 Biochemical 275 
abnormalities consistent with alteration of endocrine organs are rare, despite amastigotes associated 276 
with inflammatory lesions have been found in the adrenal cortex of leishmaniotic dogs.82,83 277 
 278 
Assessment of renal function 279 
The systemic immune complex disease that characterizes leishmaniasis induces the deposition of 280 
circulating immune complexes at the glomerular level. This induces a series of inflammatory 281 
glomerular changes detectable histologically and ultramicroscopically,36,84,85,86,87 that are primarily 282 
responsible for a proteinuric nephropathy.87 The evolution of this condition, as for any other 283 
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protein-losing nephropathy, is represented by the development of a chronic kidney disease (CKD) 284 
due to a series of factors that include progressive glomerulosclerosis, renal hypertension, overload 285 
of protein reabsorption in tubular cells, with subsequent tubulointerstitial nephritis85,87 In turn, 286 
advanced stages of CKD are characterized by hyperazotemia and may be associated with systemic 287 
hypertension, both factors contributing to comorbidity in dogs with leishmaniasis.87,88 Therefore, as 288 
for any other renal disease, the early detection of proteinuria and correct classification of CKD is 289 
mandatory in the diagnostic workup. To this aim, the clinical and laboratory approach is the same 290 
recommended by the International Renal Interest Society (IRIS)89 for any type of CKD. This 291 
approach is based on a thorough clinical evaluation of the dog, based on physical examination and 292 
diagnostic imaging, on the measurement of arterial pressure according to the guidelines 293 
recommended by the American College of Veterinary Internal Medicine (ACVIM)90 and on the 294 
quantification of urinary proteins (described in the section of this article regarding urinalysis) and 295 
markers of renal function. According to the IRIS guidelines, these include mostly the urine specific 296 
gravity and the serum concentration of creatinine.89 This latter has been shown to increase 297 
frequently in leishmaniotic dogs14,15,16,19,20,91 and early (from 12 to 18 months) following infection.27 298 
Creatinine is a good indicator of a decreased glomerular filtration rate (GFR), and it more specific 299 
than other markers such as urea92,93 but unfortunately they are not enough sensitive to detect the 300 
earliest stages of renal insufficiency. Due to the compensatory activity of residual nephrons, in fact, 301 
an increase of serum creatinine occur only when the GFR dramatically decreases.93 Therefore, 302 
although creatinine is commonly used to detect overt CKD, a huge research activity is currently 303 
running in veterinary nephrology and clinical pathology to identify earlier markers of decreased 304 
GFR, either in leishmaniotic dogs or in dogs affected by other types of CKD. The direct 305 
measurement of GFR trough clearance tests (e.g. clearance of inulin, exogenous creatinine or, more 306 
recently, iohexol) would be the best method to assess in real time the functionality of the 307 
kidneys94,95 Unfortunately these tests, although currently validated for use in dogs, are not widely 308 
available in clinical practices or in veterinary laboratories. Therefore, the diagnostic potential of 309 
14 
 
indirect markers other than creatinine has been recently investigated. Cystatin C (Cys C) has been 310 
proposed as surrogate marker of creatinine, especially using advanced measurement techniques 311 
such as particle-enhanced turbidimetric immunoassay.96-99 The serum concentration of Cys C has 312 
been assessed also in dogs with leishmaniasis.100 However, there is no evidence that serum Cys C, 313 
that is less specific than creatinine, is more sensitive that creatinine in detecting early CKD.94 314 
Promising results have been obtained by the measurement of urinary Cys C101 but this seems not to 315 
be true in canine leishmaniasis, where urinary Cys C increases only in proteinuric dogs with 316 
increased creatinine.102 Recently, a promising biomarker for early detection of renal dysfunction 317 
seems the symmetric dymethilarginine (SDMA), a catabolite of methylated proteins that is mainly 318 
excreted by the glomeruli and not reabsorbed by tubuli ,103,104 that in published report has been 319 
measured in serum using chromatographic techniques.104 Studies in cats, where the early diagnosis 320 
of CKD may be more challenging than in dogs, demonstrated that SDMA increases earlier than 321 
creatinine,105,106 although it does not provide additional advantages in animals with overt CKD (i.e. 322 
with CKD on which serum creatinine is already increased). Preliminary results indicate that SDMA 323 
may have the same role of early indicator of renal dysfunction also in dogs,104,107 although a few 324 
extrarenal variables may affect the results.108 Therefore, although no studies specifically focused on 325 
the use of SDMA in canine leishmaniasis exist, it is very likely that SDMA may be used, in the 326 
future, to assess renal function in leishmaniotic dogs that are proteinuric but still have normal 327 
creatinine concentration.  328 
Other blood markers may provide additional information in leishmaniotic patients with CKD. For 329 
example in people the increased serum concentration of homocysteine (Hcy), endothelin-1 (ET-1) 330 
or C-reactive protein (CRP) may predict, hypertension and/or inflammation, especially in 331 
association with CKD.109-113 In dogs, Hcy increases in those with CKD114 but seems to be less 332 
associated with hypertension than in humans.115 Conversely, ET-1 increases in serum of dogs with 333 
hypertension associated with early stages of CKD115 and is also associated with inflammation, as 334 
demonstrated by its correlation with CRP levels, which in turn increases mostly in CKD associated 335 
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with inflammatory conditions.113 However, the potential of these additional markers as 336 
complementary tests for the management of leishmaniotic dogs with CKD has not been 337 
investigated. Conversely, inflammatory markers such as CRP, ferritin and adiponectin have been 338 
measured in the urine of dogs with leishmaniasis and were found increased in dogs with proteinuria, 339 
sometime in the absence of elevated serum creatinine.102,116,117 These analytes might therefore work 340 
as early markers of CKD in leishmaniotic dogs, although it is more likely that their increase depend 341 
on the elevated serum concentration, thus reflecting the inflammatory state typical of leishmaniasis, 342 
rather than a direct consequence of CKD. 343 
Finally, in leishmaniotic dogs, tubulointerstitial lesions may occur secondarily to proteinuria caused 344 
by glomerular damages. Therefore, the availability of markers to identify dogs with tubular lesions 345 
would allow to early differentiate dogs with pure glomerular lesions from dogs with more advanced 346 
renal damage. Tubular markers, however, are usually measured in urine and not in serum and are 347 
described in the section on urinalysis. It is also worth mentioning that some dogs with CKD may 348 
have acute deterioration of their renal dynsfunction due to factors related or not to leishmaniasis 349 
(e.g. vomiting, diarrhea). 350 
 351 
Assessment of inflammatory/immune reactions 352 
Based on the pathophysiology above described, it is clear that leishmaniotic dogs with overt disease 353 
have an intense inflammatory reaction and produces high amount of molecules involved in the 354 
immune response, including antibodies. Both these phenomena may be investigated using tests such 355 
as protein analysis and serum protein electrophoresis or measurement of acute phase proteins 356 
(APPs).  357 
 358 
Protein analysis and serum protein electrophoresis are considered the most accurate tests to 359 
diagnose canine leishmaniasis. Protein changes appear 12-18 months after exposure to the 360 
parasite.27 Total proteins and total globulin are frequently increased, especially in the acute phase of 361 
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the disease.14,15,16,21,91,118,119 The increase of total protein can correlate with the severity of the 362 
clinical score, according to Proverbio et al.120 Moreover albumin decreases both because of its role 363 
as negative APPs (see below) and of the renal loss associated with proteinuric nephropathy leading 364 
to decreased albumin:globulin (A/G) ratio91,118,119 The decrease of the A/G ratio is so frequent that it 365 
has been considered by some Authors to be one of the more sensitive tests for canine 366 
leishmaniasis118 and hypoalbuminemia is considered a negative prognostic factor in leishmaniotic 367 
dogs since the magnitude of hypoalbuminemia negatively correlates with survival times.121 The 368 
typical electrophoretogram of leishmaniotic dogs with overt clinical signs (figure 4) displays 369 
hypoalbuminemia, an increase of α2-globulin, where most of the positive APPs migrate, and 370 
especially a strong increase of γ-globulins, due to the huge amount of circulating antibodies, 371 
immunecomplexes, and other molecules with γ motility involved in immune-mediated 372 
inflammatory reactions.119 Occasionally, peaks due to circulating antibodies are found in the 373 
β region, where IgM and some APPs migrates. The gammopaty is typically polyclonal but 374 
sometime the peak may be narrower (oligoclonal), biclonal122 or definitely monocloncal.123 The 375 
interpretation of the peak must take into account the electrophoretic method, since peaks are usually 376 
narrower using capillary zonal electrophoresis (CZE) than using agarose gel or cellulose acetate.124 377 
Therefore, CZE may lead to falsely interpret as monoclonal a peak that is ultimately oligo- or 378 
polyclonal (figure 5). Moreover, although monoclonal peaks associated exclusively with 379 
leishmaniasis have been described, the detection of monoclonal peaks should induce to consider the 380 
possible presence of concurrent diseases (e.g. other vector-borne diseases or multiple 381 
myeloma).125,126 382 
 383 
Acute phase proteins are powerful indicators of inflammation: the pro-inflammatory cytokines 384 
produced in inflammatory sites induce the so called “acute phase response”, characterized by the 385 
release of neutrophils from storage pools, by an activation of myelopoiesis (see above), and by a 386 
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modulation of protein synthesis in the liver.119 This latter phenomenon leads to a decreased serum 387 
concentration of the “negative APPs”, and to an increased concentration of the “positive APPs” that 388 
includes a series of immunomodulators, scavenger or transport proteins, antiproteases, and other 389 
proteins involved in host defenses.112 Therefore it is not surprising that the serum concentration of 390 
positive APPs in dogs with overt canine leishmaniasis is high. The list of APPs whose 391 
concentration increases in serum of leishmaniotic dogs is long and includes CRP, Haptoglobin 392 
(Hp), Ceruloplasmin (Cp) Serum Amyloid A (SAA) and ferritin,127-132 with CRP and ferritin that, as 393 
previously reported, increase also in urine. Similarly, a decrease of negative APPs other than 394 
albumin has also been reported; these are transferrin, indirectly measured as total iron binding 395 
capacity (TIBC), that induces also a reduction in the concentration of iron, and a decreased activity 396 
of the enzyme paraoxonase (PON-1).129,130,133 PON-1 is a negative APP that is bound to high 397 
density lipoproteins (HDL) and represents a link between inflammation and oxidative stress. 398 
Therefore its decrease is not constantly seen in leishmaniotic dogs but it may become evident when 399 
oxidative stress is particularly severe.133 Interestingly, in these cases also the concentration of HDL, 400 
that is converted into low density lipoprotein (LDL) after detachment of PON-1, decreases134 and 401 
may be a cheap marker of inflammation and oxidative stress associated with leishmaniasis. 402 
Recently a reduced serum activity of adenosine deaminase (ADA) and butyrylcholinesterase 403 
(BChE), two enzymes involved in modulating immune responses, has also been reported in dogs 404 
with leishmaniasis.135 405 
The APP changes summarized above are not diagnostic per se since mild increases of positive 406 
APPs have been reported also in infected dogs without clinical signs127 and severely increased 407 
levels may occur in diseases other than leishmaniasis.112 In a dog in which leishmaniasis has been 408 
diagnosed by other clinical or laboratory findings, however, the magnitude of these changes may 409 
reflect the magnitude of inflammation and thus provide prognostic information. In particular, the 410 
decrease of PON-1 is particularly evident in severe diseases and may therefore be a negative 411 
prognostic marker. Moreover, APPs may be useful to monitor the follow up. 412 
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 413 
4) Abnormalities at urinalysis 414 
The analysis of urine from dogs with suspected or confirmed leishmaniasis must be focused on 415 
three main aspects: confirmation of CKD, evaluation of proteinuria, and investigation of possible 416 
tubular damage. Urine samples should be analyzed using the usual approach followed in any case of 417 
CKD, that starts with the physico-chemical analysis and continues with sediment analysis and 418 
evaluation of proteinuria, eventually followed by the measurement of markers of tubular damages. 419 
 420 
Physico-chemical analysis 421 
According to standardized procedures,136 after centrifugation of urine to separate supernatants from 422 
the sediment, the routine physicochemical analysis must be addressed to evaluate with a 423 
refractometer the urine specific gravity (USG), that tends to decrease in dogs with tubulo-interstitial 424 
damage.93 Then, the supernatant can be used for a dipstick analysis, that should be focused on 425 
assessing: 426 
- the pH that, although not extremely accurate137 may be useful to properly interpret other 427 
dipstick results: for example the semiquantification of proteins may provide erroneously 428 
positive results in alkaline urine (pH>8); 93 429 
- the concentration of proteins, to be interpreted as described below; 430 
- the presence of glucose, that, as specified below, may be an indicator of tubular damage. 431 
Sediment analysis is another important step of urinalysis of leishmaniotic dogs: the presence of an 432 
active sediment (e.g. a sediment with high numbers of leukocytes, erythrocytes or bacteria) is 433 
important either because may indicate a lower urinary tract infection superimposed on the primary 434 
disease (leishmaniasis) or because in the presence of an active sediment, results regarding 435 
proteinuria should be carefully considered;138 conversely, the presence of granular or cellular casts 436 
may be consistent with tubular damage.93  437 
 438 
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Evaluation of proteinuria 439 
The evaluation of proteinuria is an essential step, since the presence and magnitude of proteinuria is 440 
not only a marker of kidney disease, but also a risk factor for the progression of nephropathy.139 441 
According to the ACVIM guidelines,140 proteinuria should be assessed in any dog with diseases 442 
potentially inducing this condition, such as leishmaniasis. The ACVIM guidelines recommend to 443 
collect urines by cystocentesis, to avoid contamination from the lower urinary tract, however, to 444 
improve the possibility to frequently monitor dogs at risk to develop proteinuria, a first evaluation 445 
may be done on voided samples, since results recorded with the two methods of collection overlap 446 
when the sediment is inactive.141 Additionally, it may be appropriate to screen the possible presence 447 
of proteinuria using a dipstick, since it has been demonstrated that if the dipstick is negative or the 448 
dogs is likely non proteinuric according to the IRIS classification89 and any additional evaluation of 449 
proteinuria is therefore not necessary.142 Conversely, if the dipstick is positive it is very likely that 450 
the dog is proteinuric and the protein to creatinine (UPC) ratio must be run to quantify the level of 451 
proteinuria. Similarly the UPC ratio must be measured in dogs with a weakly positive dipstick 452 
result but with a low USG, in order to understand if the weak positive result really reflect the 453 
presence of proteinuria or not. 142 In all the cases above, the UPC ratio must be measured to 454 
definitely classify the dog as proteinuric (UPC >0.5), borderline proteinuric (UPC= 0.2-0.5) or non 455 
proteinuric (UPC <0.2) according to the IRIS classification, recently revised for the diagnosis of 456 
glomerular disease.89,143 In the interpretation of data, particular attention should be paid on results 457 
close to these threshold since results may be affected by analytical variability or by the type of 458 
reagent or laboratory procedures used to measure urinary proteins.144-146 Then, especially if the dogs 459 
is borderline proteinuric or proteinuric, quantification of proteinuria must be repeatedly assessed (at 460 
least 3 times in 2 weeks) because, according to the ACVIM guidelines,140 additional investigations 461 
or treatments should be performed only if persistent proteinuria is confirmed by repeated urinalysis. 462 
Alternatively, the analysis of proteinuria can be done on pooled urine samples, in order to reduce 463 
the possible influence of circadian variations in renal protein excretion.147 Finally, according to the 464 
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ACVIM guidelines140 the origin of urinary protein should be assessed through a renal biopsy. 465 
However, according to the recent IRIS guidelines143 renal biopsy is recommended only in the case 466 
of rapid progression of CKD or in dogs not responding to conventional treatments. Alternatively, 467 
the origin of proteinuria can be argued on the basis of surrogate methods such as qualitative analysis 468 
of urinary proteins (see below). However, in the case of very high UPC ratio, as usually occur in 469 
leishmaniotic dogs, proteinuria is mostly of glomerular origin and tubular proteinuria, if present, 470 
contributes only partially to the concentration of urinary proteins.  471 
 472 
Markers of tubular injury 473 
Although the gold standard method to identify the origin of proteinuria is the histological analysis 474 
of renal biopsies, due to its invasiveness this technique is rarely applied in leishmaniotic dogs. 475 
However, in order to differentiate the dogs with a tubular component of proteinuria, that are in a 476 
more advanced stage of renal disease, urinary markers may be used.148 Some rough markers such as 477 
granular or cellular casts and glycosuria in normoglycemic dogs are very specific indicators of 478 
tubular damage, but are not enough sensitive and therefore do not detect dogs with early tubular 479 
damage. Additionally, tubular damage so severe to induce glycosuria are rarely observed in 480 
leishmaniotic dogs. Early information about the presence of tubular damage may be achieved using 481 
sodium dodecylsulphate (SDS) electrophoresis of urinary proteins or measuring the concentration 482 
or some urinary analyte or the activity of some urinary enzymes. The SDS denaturates and charges 483 
negatively the urinary proteins. Therefore, after migration on polyacrylamide gel (SDS-PAGE) or 484 
agarose gel (SDS-AGE), proteins migrate according their molecular mass.149 This allows to 485 
differentiate large proteins, that are of glomerular origin, from small proteins, that are of tubular 486 
origin. Results of SDS-PAGE have been shown to well correlate with results of renal biopsies, 487 
especially for the identification of glomerular damage or of severe tubule-interstitial damages.150-151 488 
while SDS-AGE, that is more diffuse in veterinary laboratories because it may be fully automated 489 
and is more rapid, cheap and less toxic that SDS-PAGE.151 However, SDS-AGE has some 490 
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analytical limitations:152 it is more susceptible to the concentration of urine thus potentially 491 
providing false positive or false negative results in very concentrated or very diluted urine, 492 
respectively, and may suffer from pre-analytical artifacts such as bands due to storage artifacts or to 493 
proteins originating in the male genital tract.153,154 However, using SDS-AGE it has been 494 
demonstrated that most of the leishmaniotic dogs have a mixed (glomerular and tubular) pattern and 495 
only a minority of dogs, likely those with less “chronic” CKD, have a pure glomerular 496 
proteinuria.84,155 Occasionally, some leishmaniotic dogs has low molecular weight proteinuria with 497 
no signs of glomerular disease, likely due to a free light chain proteinuria (i.e. a pre-renal 498 
proteinuria associated with the intense antibody production) rather than to a tubular damage.156  499 
Enzymuria is considered a good marker of tubular damage, since the enzymes of interest are usually 500 
located in the cytoplasms of tubular cells. Therefore, they may be found in urine when tubular cells 501 
are damaged. Several enzymes may be used for this purpose but the two most popular are γ-502 
glutamyl transferase (GGT) and N-acetyl-β-N-glucosaminidase (NAG)93,157 that must be measured 503 
just after sampling since their activity decreases after refrigeration or freezing.158 Increases of these 504 
enzymes, as well as of other enzyme such as alkaline phosphatase (ALP) or β-glucuronidase, have 505 
been reported in dog with leishmaniasis159 and the increase of GGT activity has been showed to 506 
correlate with the presence of tubular bands in SDS.155 On the contrary, no information is available 507 
on the utility in leishmaniotic dogs of the measurement of other urinary analytes such as clusterin, 508 
kidney injury molecule 1 (Kim-1), neutrophil gelatinase-associated lipocalin (NGAL) or retinol 509 
binding protein (RBP), used in pharmacology to assess the presence of renal tubular damages and 510 
that have been shown to be potentially useful markers in dogs with CKD.148,160-162  511 
 512 
Tests for etiological diagnosis that may support or confirm leishmaniasis 513 
Tests for etiological diagnosis are used to identify the presence of the parasite or its components 514 
(direct tests) or the host’s response to the parasite (indirect tests). As previously mentioned, positive 515 
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indirect tests (serology) may or may not indicate a current infection. Conversely, positive direct 516 
tests (cytology, histology, immunohistochemistry, PCR, culture and xenodiagnosis) demonstrate 517 
that the dog is actually harboring Leishmania and it is therefore infected. However, as stated above, 518 
the relationship between infection and disease should be based on the evaluation of clinical findings 519 
and clinicopathologic tests. The most common tests for etiological diagnosis are described below. 520 
 521 
1) Serology 522 
Methods 523 
Apart from some techniques such as Western blotting, that is highly accurate but not available in 524 
routine practice, or other methods that have been proposed but are not extensively used, such as 525 
latex agglutination or methods based on the detection of antibodies through immunosensors or flow 526 
cytometry,163-166 the most common techniques used to detect antibodies are based on three 527 
analytical principles: immunofluorescent antibody test (IFAT), enzyme-linked immunosorbent 528 
assay (ELISA) and immunochromatographic test (ICT). ICT is the basis of all-rapid “in clinic” 529 
assays, which have a major limitation being that they provide results in a qualitative manner (i.e. 530 
presence/absence of specific reactive bands).167 Several commercial ICT kits are available, which 531 
employ single or multiple recombinant Leishmania antigens to be used on serum, plasma, whole 532 
blood or blood spots dried onto filter paper.168Several studies have evaluated their diagnostic 533 
performances and, in general, they reach similar conclusions: while specificity is quite acceptable, 534 
ICT sensitivity is usually low (in the approximate range of 30-70%).169 Lowest sensitivities are 535 
found in infected dogs without clinical signs, the highest ones in those with overt disease.170 536 
Therefore, ICT may be used as a first “in clinic” test to complete the laboratory evaluation of 537 
clinically suspected dogs and, in case of positivity, serology should be repeated by ELISA or IFAT, 538 
which provide quantitative results (see below). However, due to the low sensitivity of the ICT test, 539 
a negative result may be falsely negative and therefore, if the clinical suspicion persists, tests with 540 
higher sensitivity (i.e. IFAT or ELISA) should be performed, Recently, a ICT kit claiming detection 541 
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of antibodies developed after natural infection but not those elicited by vaccination with the LiESP-542 
based vaccine, has been proposed as a tool to differentiate vaccinated from infected dogs.171 The 543 
principle of the test is sound, and the first studies reported an elevated sensitivity of this ICT 544 
format;172 however, other studies reported a low sensitivity also for this test.173  545 
IFAT is recognized as the reference method to perform anti-Leishmania serology in dogs,169,174 as it 546 
is very sensitive and also highly specific except in areas endemic for the New World parasite 547 
Trypanosoma cruzi, that may give false positive results; values approach 100% for both the 548 
parameters. ELISA is also very sensitive and specific when a combination of immunodominant, 549 
recombinant proteins are used as antigen, whereas it has slightly lower specificity when crude 550 
parasite lysates are employed instead.167,173-175 Compared to IFAT, that is based on the evaluation of 551 
promastigote fluorescence at UV microscope and is therefore operator-dependent), ELISA is easier 552 
to standardize since results are read by an automated spectrophotometer. Both IFAT and ELISA 553 
have the advantage to provide quantitative results that are based, respectively, on the final antibody 554 
titer (the last sample dilution providing positive result) and optical density values that can be 555 
compared with reference titred samples using conversion factors. Based on the unavoidable 556 
variability due to operator-dependent or analytical (antigen stability, antiserum or equipment 557 
performances) parameters, precise anti-Leishmania antibody titers are not universally available. 558 
Hence, a titer is considered “high” if it is 4 fold higher than the threshold value of the laboratory.15 559 
Similarly, 4 fold variations in titers of sequential samples of the same dog should be expected in 560 
seroconversions, or in the outcome of therapy. Hence, sequential samples must be analyzed by the 561 
same method in the same laboratory. 562 
 563 
Interpretation 564 
Serological tests detect and quantify the presence of antibodies in serum or plasma. Antibodies can 565 
be found in blood as soon as 1 month after exposure to infected phlebotomines, although the 566 
median time for seroconversion is about 5 months in natural conditions and 3 in experimental 567 
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studies).176 Therefore is very likely that dogs living in highly endemic regions seroconvert during 568 
the sand fly activity period (from late spring to early autumn in temperate zones, all over the year in 569 
tropical ones),9 If the infection is efficiently controlled by the host’s immune responses, the 570 
antibody titers, when present, tend to remain low and therefore these clinically-healthy dogs are 571 
classified as exposed or infected.15 Conversely, the uncontrolled parasite dissemination is associated 572 
with an exaggerated humoral response and therefore antibody titers are high when the disease is 573 
evident. This condition is classified as “sick dog” or “severely sick dog” by CLWG classification, 574 
and stage III or IV (severe or very severe disease) by Leishvet classification.14 Furthermore, a direct 575 
relationship between the clinical score and antibody titers exists.120,177 However, dogs with clinical 576 
signs (sick) and low-medium antibody titers may also be detected. These have been classified as 577 
stage I or II (mild or moderate disease) according to the Leishvet classification.14 578 
Therefore, quantitative serology should always be performed when, despite strong clinical suspicion 579 
of leishmaniasis, lesions approachable by fine needle aspiration are not present or when cytological 580 
analysis of lesions (including lymphoid organs and bone marrow) does not reveal the typical pattern 581 
associated with leishmaniasis, despite a possible PCR positivity. In this case a high antibody titer is 582 
often consistent with the disease, while, if the antibody titer is low, leishmaniasis should be 583 
considered only if any other disease potentially responsible of the clinical presentation is ruled 584 
out.14,15 585 
 586 
2) PCR 587 
Methods 588 
As for serology, several molecular methods have been proposed to detect the presence of the 589 
parasite DNA in various biological samples. Some of these methods are not commonly used or 590 
recently validated, such as the non-amplification assay based on the use of probes labelled with gold 591 
nanoparticles178 or the loop-mediated isothermal amplification (LAMP).179,180 Conversely, 592 
conventional PCR, nested PCR and quantitative (real time) PCR are widely used in routine 593 
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practice.14,15,169,174 PCR sensitivity and specificity varies according to the method and especially 594 
according to the target DNA sequence. Most of the PCR tests currently used are targeting multicopy 595 
DNA sequences, such as the small subunit ribosomal RNA genes or the kinetoplast DNA 596 
minicircles, thus increasing the sensitivity of the test.181 Compared with conventional and nested 597 
PCR, the quantitative PCR techniques offer two main advantages:182 they are usually run in close 598 
systems and are therefore less prone to contamination, and provide information about the copies of 599 
DNA that are present in the sample. This latter aspect may be relevant during the follow up to 600 
monitor the efficacy of leishmanicidal treatments and therefore it may advisable to use quantitative 601 
PCR at first diagnosis (before any treatment), in order to have a baseline value for further analyses 602 
during the follow up182,183 However, it does not seem that quantitative PCR techniques are more 603 
sensitive than conventional or nested PCR to diagnose leishmaniasis in dogs.184 One additional 604 
limitation of quantitative PCR is that standardized methods to accurately quantify the copies of 605 
DNA may not be offered by some laboratories. 606 
 607 
Samples 608 
PCR techniques may be applied virtually on any tissue or biological fluids. Theoretically, it may be 609 
superfluous to use molecular tests in affected tissues in which amastigotes have been visualized by 610 
cytology or histology (see below). However, cytology and histology are less sensitive than PCR 611 
(see below) and therefore, a negative cytological result does not exclude that amastigotes are 612 
present. Therefore, when a fine needle aspirate or a tissue biopsy is performed, it may be advisable 613 
to use part of the material to prepare cytological or histological specimens and to store the 614 
remaining sample as recommended by the laboratory (usually frozen, fixed in 95% ethyl alcohol or 615 
in appropriate preservatives) to run PCR in case amastigotes cannot be visualized despite the 616 
cytological or histological pattern is highly consistent with leishmaniasis. If needed, PCR may also 617 
be performed on cytological material already fixed on glass slides185 or on formalin fixed and 618 
paraffin embedded material.186,187 619 
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In routine practice PCR is rarely run on injured tissues, for which cytology and histology are 620 
preferred. When lesions are not present, or they are not approachable by fine needle aspiration or 621 
biopsy (for example when the prevalent clinical presentation is anemia or proteinuric nephropathy), 622 
other samples are preferred. Several studies demonstrated that bone marrow and/or lymph nodes 623 
and spleen provide the highest sensitivity in detecting Leishmania by PCR, especially in sick 624 
dogs,14,188-192 pending that the quality of the sample is adequate, especially for the lymph node. 625 
Parasite DNA can be easily found in the skin, including intact tissue especially in the facial region 626 
or in the ears. Recent studies demonstrated that conjunctival and, to a lesser extent, oral and nasal 627 
swab material is very sensitive for the detection of Leishmania DNA and, in addition, can provide 628 
positive results earlier than other tissues188,190,193-196 Buffy coat or whole blood may also be used for 629 
conventional or quantitative PCR analysis. Although its sensitivity is lower than that of the other 630 
tissues cited above, it can be collected without invasive methods and in the case of positive results 631 
provide a diagnostic information in a rapid and cheap way14,15 632 
 633 
Interpretation 634 
When interpreting PCR results it must be kept in mind the difference between infected and sick 635 
dogs. Ultimately, the detection of the parasite’s DNA indicates that the dog is infected. The 636 
correlation between infection and disease should be based on the presence of clinical signs and 637 
laboratory abnormalities. From this perspective, the detection of Leishmania DNA in lesions with 638 
cytological or histological patterns highly consistent with leishmaniasis (see below) supports the 639 
diagnosis of disease and, similarly, a positive PCR in blood or bone marrow of a dog with systemic 640 
signs of leishmaniasis can support the diagnosis of disease. Conversely, positive results in dogs 641 
without signs clearly referable to leishmaniasis do not support the hypothesis that the infected dog 642 
is also affected by clinical leishmaniasis, unless any other possible disease is excluded. For 643 
example, a transient PCR-positivity in bone marrow may be found a few months from the natural 644 
exposure to sand fly bites, without necessarily meaning that the dogs is infected or sick.9 Similarly, 645 
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the PCR positivity in intact skin of a dog living in an endemic area does not necessarily suggest that 646 
the presence of parasites in the skin will be followed by parasite dissemination throughout other 647 
body tissues.10-13 Skin positive PCR results may in fact be dependent on the presence of recently-648 
inoculated promastigotes, or of amastigotes recently phagocytosed by resident macrophages that, in 649 
“resistant” dogs, may efficiently control the infection at local level.188,192,197 650 
 651 
3) Cytology 652 
Samples and methods 653 
Fine needle aspiration should be performed in all cases showing cutaneous papular or nodular 654 
lesions and/or lymph node enlargement.15 Ulcerative cutaneous lesions can be sampled by scraping 655 
the lesion or using less invasive methods such as imprint smears. Additionally reports describing 656 
the presence of amastigotes and associated lesions in nodular masses with atypical localization, 657 
such as the tongue,29,33 the testis,198-199 and oral or nasal masses200 have been reported and therefore 658 
any nodular lesion in dogs with clinical or laboratory signs potentially consistent with leishmaniasis 659 
(e.g. anemia, CKD, alterations of the electrophoretograms, positive serology) should be sampled by 660 
fine needle aspiration. Nasal lesions may also be sampled using brush cytology201 Similarly, when 661 
clinical or clinicopathological pattern is consistent with leishmaniasis, the possible presence of 662 
Leishmania should be investigated also in pathological body fluids such as joint fluids,25,26 663 
effusions,41 or cerebrospinal fluid although in this latter sample, cellularity is usually so low that 664 
PCR may identify the parasite better than cytology.77 In all these cases, fluid samples must be 665 
collected by centesis, following the procedures routinely recommended for each site. 666 
When cutaneous lesions or nodular lesions in other organs, lymph node enlargement, abnormal 667 
accumulation of fluids are absent but the clinical suspicion of leishmaniasis is high, the possible 668 
presence of parasites should be investigated in organs rich of cells of the monocyte-macrophage 669 
system, such as bone marrow, lymph nodes or spleen14,15,60 670 
 671 
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Interpretation 672 
Cytology aims to demonstrate the presence of amastigotes that are usually found within the 673 
macrophages and, when the parasite burden is high and cell lysis occurs, also on the background 674 
(figure 6). The detection of amastigotes may be difficult in cutaneous ulcerative lesions, where the 675 
presence of necrosis and cellular debris or of contaminating bacteria may mask the presence of 676 
amastigotes. Attention should be paid to misinterpret as amastigotes cellular or granular debris that 677 
may be present in these lesions.  678 
Additionally, cytology may allow to detect the typical inflammatory patterns associated with 679 
leishmaniasis, that are usually characterized by pyogranulomatous inflammation associated with a 680 
moderate to severe lymphoplasmocytic infiltration in skin or nodular lesions with atypical 681 
localization (figue 5) and, in lymph nodes, by a reactive hyperplasia of variable severity, 682 
characterized by lymphoplasmocytic and macrophagic infiltration, usually associated with 683 
numerous neutrophils.60,202,203 Similarly, cytologic patterns typically associated with leishmaniasis 684 
may be found in the bone marrow, as described in details in the section dedicated to hematology. 685 
Neutrophils, lymphocytes and macrophages can be found also in body fluids of dogs affected by 686 
leishmaniasis. Additionally, the fluids may show the features typical of inflammation such as high 687 
cell counts and protein contents and, in joint fluids, decreased viscosity and negative mucin clot 688 
test. 25,26,41,77,204,205 689 
The diagnosis of leishmaniasis is easy when amastigotes are detected in samples that shows the 690 
cytologic patterns described above. However, when cytologic patterns consistent with leishmaniasis 691 
but no amastigotes are seen, leishmaniasis should not be ruled out, since it is known that the 692 
diagnostic sensitivity of cytology is low.169,174 In these cases, tests that have higher analytical and 693 
diagnostic sensitivity, such as PCR, must be run. Alternatively, affected tissues can be biopsied to 694 
perform histology and immunohistochemistry, as described below. Conversely, when amastigotes 695 
are seen in the absence of cytological abnormalities, or cytology is done on bone marrow, lymph 696 
node or spleen, positive results must be interpreted carefully, as systemic signs may be due to 697 
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diseases other than leishmaniasis.15 Similarly, a diagnostic workup to confirm or exclude 698 
leishmaniasis (i.e. the clinical disease associated with infection) should be run when Leishmania is 699 
incidentally found in lesions that clearly have a different origin. For example, several reports 700 
describe the association between the presence of amastigotes and tumors such as lymphoma, 701 
transmissible veneral tumors and other types of neoplasia.206-211 On a practical standpoint in these 702 
cases it is important to understand if the dog is affected by both diseases or affected by a neoplastic 703 
disease and simply infected with Leishmania. 704 
 705 
4) Histology 706 
Histology can demonstrate the presence of Leishmania in routinely hematoxylin and eosin stained 707 
sections when cytology provides parasite-negative results in tissues having a cytological pattern 708 
highly consistent with leishmaniasis. Compared with PCR, histology has two main disadvantages: it 709 
can be more laborious and time consuming, and the identification of amastigotes may be more 710 
difficult than in cytological samples. As for the latter, amastigote presence can be confirmed by 711 
immunohistochemistry (figure 7),36,212 in situ hybridization213,214 or PCR on formalin-fixed and 712 
paraffin embedded samples.186,187 On the other hand, histology has the advantage to provide 713 
additional information on the cytoarchitectural pattern of the lesions. This is a great advantage since 714 
it may allow to discriminate dogs in which the parasite is associated with typical lesions from those 715 
in which the infection does not seem to be associated with the disease. Therefore, according to some 716 
guidelines,22 histology should always be performed, especially in the case of cutaneous lesions. The 717 
interpretation of histological results is facilitated by the elevated number of papers describing the 718 
distribution of parasites and the lesions associated with active disease, mostly characterized by 719 
lymphoplasmacytic or granulomatous-pyogranulomatous inflammations and/or by vasculitis either 720 
in organs usually affected by Leishmania (bone marrow, spleen, skin, lymph nodes, kidney, etc) but 721 
also in unusual sites such as heart, lung, adrenal gland, genital tract, central nervous system, skeletal 722 
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muscle, gastrointestinal tract, nails, lacrimal glands and ocular muscles.23,24,29-31,33,36,74,76-78,80-82,84-723 
86,156,202,215-221  724 
 725 
5) Parasite culture and biological test for infectiousness (xenodiagnosis) 726 
Conclusive diagnosis of active infection should be based on tissue cultures, which not only confirm 727 
whether dogs harbor parasites, but also demonstrate that the protozoa is viable and multiplies 728 
actively. A diagnostic Leishmania culture, which differs from maintenance culture of laboratory-729 
adapted strains, requires biphasic blood-agar media that need fresh components.75 A conclusive test 730 
for infectiousness (xenodiagnosis) requires that naive (laboratory-reared) sand flies are induced to 731 
feed on infected dogs and are examined thereafter for the presence of promastigotes in the gut.222 732 
However both tests are unpractical, since on one hand specific blood-agar media are unavailable 733 
commercially for diagnostic Leishmania culture and must be prepared in laboratory, on the other 734 
hand only a few centers breed sand flies for diagnostic purposes. Therefore these tests are mainly 735 
intended for research and cannot be recommended for routine practice.  736 
 737 
Future perspectives 738 
Several studies investigated the diagnostic potential of innovative markers in dogs with 739 
leishmaniasis: for example, the measurement of iron superoxide dismutase (Fe-SODe) secreted by 740 
the parasite has been evaluated as a possible marker of infection;223 proteomic analysis revealed a 741 
series of proteins that are over- or under-represented in leishmaniotic dogs;224 the analysis of the 742 
expression of cytokines or molecules such as leptin or inducible nitric oxide synthetase (iNOS) in 743 
blood or tissues revealed different profiles in leishmaniotic dogs compared to controls11,13,225-227 744 
high levels of matrix metalloprotieinases (MMP), and especially of MMP9 and pro-MMP2, have 745 
been reported in serum or CSF of leishmaniotic dogs.228,229 However, none of the studies provided, 746 
to date, exhaustive information on the possible utility in practice of these markers. However, the 747 
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information provided in these investigations is useful to design future research and explore their 748 
potential clinical application. 749 
Similarly, the attention of researchers has been recently focused on markers of oxidative stress; 750 
inflammation is characterized by the release of reactive oxygen metabolites from phagocytes 751 
recruited in inflammatory sites and this leads to a consumption of antioxidant compounds.230 752 
Increases of oxidants or oxidized molecules (e.g. reactive oxygen metabolites, malonyldialdeide, 753 
lipoperoxides, thiobarbituric acid reacting substances) and decreases of antioxidant compounds 754 
(total antioxidant capacity, trace elements, paraoxonase) have been reported in leishmaniotic 755 
dogs130,133,134,231-234 Unfortunately, only a few studies assessed the diagnostic potential of oxidative 756 
markers. for example, the diagnostic performance of ROS were not excellent, likely because 757 
oxidative phenomena are intense when inflammation is superimposed to Leishmania infection 758 
during the clinically overt phase, but depressed if macrophages have been recently infected, due to 759 
the ability of the parasite to inhibit the production of oxygen radicals by phagocytes.7,8,234  760 
 761 
Tests for monitoring the post-treatment follow up 762 
Laboratory tests during the follow up should be focused in monitoring possible toxic effect of 763 
treatment as well as the clinical and the parasitological status of the patient following administration 764 
of drugs according to conventional treatments protocols. These mainly include the administration of 765 
antimonials and allopurinol or of miltefosine and allopurinol. Treatments different from those listed 766 
above should be carefully considered only when conventional treatments are not effective.235  767 
 768 
Monitoring the possible toxic effect of treatment 769 
Theoretically, the possible toxic effects of treatment should be monitored. However, despite some 770 
studies reported possible nephrotoxicity of antimonials,85,236 others did not confirm this finding,237 771 
and recent investigations demonstrated that no toxic effects on heart or pancreas are induced by 772 
these drug category in dogs, differently from what is observed in humans.238,239 Therefore, toxic 773 
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effects should be monitored only in selected dogs, particularly when peculiar clinical findings are 774 
present or history might lead to hypothesize any drug adversity. The only possible adverse effect of 775 
allopurinol is the formation of xanthine crystals, and possibly urolithes, in urine.240 These occur 776 
very frequently and may be sometime abundant although associated clinical signs and urolith 777 
formation are less common and suspension of treatment is unusual. Therefore, the analysis of urine 778 
sediment should be always included in the laboratory workup when allopurinol is included in the 779 
treatment protocol or when urine appears macroscopically turbid or forms an evident pellet after 780 
centrifugation (figure 8).  781 
 782 
Monitoring the clinical status 783 
The clinical presentation of leishmaniotic dogs may be extremely variable. Therefore, it is not 784 
possible to define, a priori, a common and standardized laboratory work up to be used during the 785 
follow up. However, two main aspects need to be monitored each time, namely the presence of 786 
renal disease and inflammation.  787 
Renal function should be evaluated through the analysis of serum concentrations of creatinine and, 788 
especially, through sequential quantification of proteinuria, due to its role as a risk factor for the 789 
progression of CKD.139 Proteinuria has been recently shown to be a negative prognostic factor in 790 
leishmaniotic dogs.121 After conventional leishmanicidal treatment, the degree of proteinuria 791 
decreases in 4-8 weeks,241 thus, additional pharmacological treatments for proteinuria should be 792 
decided thereafter. The possibility to restore normal renal function depends on the severity of renal 793 
damage at the time of first diagnosis. Therefore, creatinine and proteinuria should be repeatedly 794 
assessed during the follow up. The frequency of testing depends on the severity of CKD: dogs in 795 
IRIS stages 3 or 489 should be frequently tested also during the treatment period. Conversely, dogs 796 
in IRIS stages 1 or 289 should be tested at the end of the first treatment cycle and then every 6-12 797 
months.242 This latter approach is also recommended by the IRIS Glomerular Disease Study 798 
Group,243 that suggests to evaluate renal functions one month after the end of leishmanicidal 799 
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treatment, and to decide the frequency of further testing depending on the post-treatment IRIS 800 
stage: specifically, tests should be run after 12 months in stage I dogs, every 6 months in dogs in 801 
stage 2, every 3 months in dogs in stage 3 and avery 6 weeks in dogs in stage 4. 802 
The inflammatory status may be monitored through sequential analysis of electrophoretograms and 803 
of acute phase proteins, whereas the simple evaluation of total protein, albumin or A/G ratio, may 804 
not be helpful because it is very likely that, despite treatment decreases globulin concentrations, 805 
albumin concentrations remain low in dogs with persistent glomerular damage and proteinuria, in 806 
turn leading to only minor changes in the A/G ratio. Differently, serum protein electrophoresis 807 
allow to detect a progressive decrease of α-and γ-globulins. These decreases start to become evident 808 
after 2-3 weeks and 4-6 weeks, respectively, following treatment with antimonials.244 Therefore, the 809 
first useful electrophoretogram to monitor the efficiency of treatment should be run not earlier than 810 
one month after treatment begin.242 The complete normalization of electrophoretograms, however, 811 
requires at least 90-120 days240 If after 2-3 months the electrophoretograms still show abnormal 812 
profiles, the possible presence of concurrent diseases such as other vector-borne diseases should be 813 
considered, especially if the gammopathy tends to be characterized by narrower peaks (see figure 814 
4). Treatments with miltefosine or with other drugs may require longer times to be beneficial (more 815 
than 2 months to observe a decrease in γ-globulins) and are also characterized by more frequent of 816 
relapses after transient normalization of laboratory profiles.245,246 Compared with serum protein 817 
electrophoresis, monitoring the concentration of APPs provides earlier information regarding the 818 
success of treatments with antimonials. CRP and SAA start to decrease in two weeks after treatment 819 
and may return within the reference intervals in about one month.131,132,244 The normalization of 820 
PON-1 and HDL is even more rapid: significant increases may be observed 3-7 days after treatment 821 
and values return within the reference intervals in two weeks.112,244 Therefore, to assess the efficacy 822 
of treatment, it may be advisable to measure the serum activity of PON-1 or the concentration of 823 
HDLs or APPs 1-2 weeks after the first administration of drugs, when other clinical or 824 
clinicopathological changes are likely still abnormal. 825 
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 826 
Monitoring the parasitological status 827 
As at first diagnosis, the parasitological status can be monitored indirectly, through the assessment 828 
of antibody titers, or by direct evaluation of the parasite presence. 829 
In case of successful treatment, a decrease of antibody titers may be expected over time; serology 830 
can be repeated during the follow up. However, antibody titers tend to decrease at least 6 month 831 
after treatment with antimonials combined with continuous allopurinol administration.240 Hence, 832 
serology should not be included in the first laboratory tests performed shortly after treatment to 833 
monitor the clinical status. Antibody titers should be determined during subsequent evaluations.242 834 
With regard to serological results, it should be kept in mind that a complete negativization of 835 
antileishmanial antibodies is unlikely, especially for dogs living in endemic areas that may be 836 
repeatedly exposed to the parasite, boosting the antibody response. Therefore, sequential serological 837 
tests during the follow up should aim to assess whether antibody titers decrease to values consistent 838 
with the simple exposure (i.e. to less than 4 folds the threshold value of the laboratory).15 839 
In order to assess whether treatment completely eradicates the infection, ideally the presence of 840 
parasites should be assessed in the tissues in which the parasite may establish a latent infection and 841 
using very sensitive techniques. For this purpose the residual parasites burden should be evaluated 842 
with repeated quantitative PCR analyses on bone marrow, spleen or lymph nodes, if still palpable.15 843 
However this procedure is invasive and it is difficult that owners accept the analysis, especially if 844 
treatment has been successful and the dog is clinically healthy. Therefore, in routine practice the 845 
evaluation of treatment efficacy is usually assessed with serology or quantitative PCR analysis in 846 
blood. If treatment is successful, the latter test may show a clear decrease of the Leishmania DNA 847 
copies after 3 to 6 months of therapy, with complete negativization occurring between 6 and 12 848 
months.182  849 
 850 
Conclusive remarks and recommended protocols 851 
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Diagnosing leishmaniasis in dogs may be difficult due to the complex pathogenesis and broad 852 
spectrum of clinical and clinicopathological findings. Hence tests that need to be included in the 853 
diagnostic protocol vary in each case or epidemiological scenario.247 854 
In clinically healthy dogs living or having travelled to an endemic area serology may be the test of 855 
choice to assess any possible exposure to parasites. Based on the median time to achieve 856 
seroconversion,176 serology should be performed at least 6 months after exposure, or periodically 857 
(e.g. every 6 months-1 year) in dogs living in endemic areas. If serology is positive, it is important 858 
to quantify the antibody response: a low antibody titer may be consistent with exposure or an early 859 
phase of infection, while a high antibody titer may sugges infection or disease.14,15 Therefore, the 860 
subsequent diagnostic steps should confirm the suspected infection through cytological and PCR 861 
analysis of sensitive tissues, and/or identification of possible clinical or laboratory alterations, 862 
especially in dogs with high antibody titers. If serology or PCR is positive and tests have been 863 
performed beyond the transmission season, the laboratory workup should identify the most common 864 
abnormalities of dogs with leishmaniasis but no clinical sign (e.g. anemia, abnormal serum protein 865 
electrophoresis, proteinuria). If changes are detected, additional clinical or laboratory tests must be 866 
performed in order to stage the disease (e.g. tests recommended by the IRIS guidelines for CKD,89 867 
tests to quantify the acute phase response of inflammation). 868 
If the dog is examined because clinical abnormalities are evident, the veterinarian should try to 869 
sample any accessible lesion to obtain cytological smears.15 If amastigotes are documented and the 870 
cytological pattern is consistent with leishmaniasis the dog is considered sick; thus, next diagnostic 871 
steps should clarify whether a systemic involvement is also present (e.g. hematological disorder, 872 
inflammation, nephropathy) and quantify the antibody titer or parasite burden with quantitative 873 
PCR to obtain baseline values useful during treatment follow-up. Conversely, if amastigotes are not 874 
observed but cytological patterns are consistent with leishmaniasis, the lesion can be further 875 
analyzed by histology combined with immunohistochemistry, in situ hybridization or PCR.14,15 A 876 
positive result with one of these additional tests should lead to investigate further the general health 877 
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status of the sick dog; conversely, if tests are negative, the presence of infection should be assessed 878 
in the bone marrow through cytology and/or PCR and, in case of positive results, further 879 
clincopathological tests should be performed as above.14,15 Regarding serology, its use is advisable 880 
to confirm the disease in dogs suspected to have leishmaniasis but yielding no parasites at 881 
cytological examination. Higher titers are more likely to occur in dogs with leishmaniasis and a 882 
more severe clinical presentation. 883 
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